Becton, Dickinson and Company (BDX) continues to remain in the spotlight within the biotech market. Its
PT has been set at
$280.14 by multiple brokerages. Despite concerns about the company's debts, the firm's strong financial performance and reasonable valuation maintain investor confidence in the stock. The
Madison Investors Fund recently sold its shares in
BDX. Yet, firms like
Empowered Funds LLC and
Lord Abbett & CO. LLC have grown their stakes, and the company received an average rating of 'Moderate Buy' from analysts. Becton, Dickinson and Company recently warned of delays in its blood culture products, albeit they are actively trying to tackle blood culture vial shortages. It also exceeded its Q2 earnings estimates and raised its fiscal 2024 guidance. The firm is geared up for its Q1 earnings and appears well on its way to achieving its
2025 commitments. Recently, BDX sealed a deal to acquire the critical care product group from Edwards Lifesciences for $4.2 billion. Despite lower than expected guidance for 2024, the company was recently named among Fortune's most innovative companies.
Becton Dickinson and BDX News Analytics from Thu, 09 Nov 2023 08:00:00 GMT to Sat, 20 Jul 2024 06:51:26 GMT -
Rating 5
- Innovation 6
- Information 7
- Rumor 2
